
    
      This is a Manocept Platform phase 2b, open-label, multi-center, multinational,
      non-randomized, single-dose study designed to assess the relationship between quantitative Tc
      99m tilmanocept planar imaging and synovial histopathology in subjects clinically diagnosed
      with RA.
    
  